GA 601
Alternative Names: GA-601Latest Information Update: 28 Feb 2024
Price :
$50 *
At a glance
- Originator Galt Pharmaceuticals
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Musculoskeletal pain
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for clinical-Phase-Unknown development in Musculoskeletal-pain in USA
- 06 Jan 2021 Clinical trials in Musculoskeletal pain in USA (Galt Pharmaceuticals pipeline, January 2021)